viewSummit Therapeutics PLC

Bob Duggan: Meet the US biotech billionaire taking a 49% stake in Summit

Duggan is said to be keen to finance the development of new antibiotics, with many viruses becoming increasingly resistant to the current cohort already out there

bob duggan
Duggan is a keen surfer and is reportedly one of Scientology’s top donors

Summit Therapeutics PLC (LON:SUMM) shares surged on Monday after it was confirmed that US biotech billionaire Bob Duggan is to take a large stake in the antibiotics specialist.

Duggan has agreed to plough US$25mln into Summit, which will leave him with just shy of 49% of the shares once all the papers have been completed.

WATCH:Summit Therapeutics welcomes investment from US billionaire ahead of busy Q1

IN-DEPTH: What has Duggan got himself in Summit?

Many investors have been speculating why he has decided to invest such a handsome sum – and at a premium – but it appears the answer might be very simple: he likes what he sees.

According to people close to the transaction, the 74-year-old has been looking to invest in antibiotics having recognised the need for more drug development in the space.

He is understood to like Summit’s intellectual property (IP), including its ridinilazole C. Diff treatment, as well as the strategy of the management, whom he is said to know and respect.

Likes the tech and the strategy

That partly explains why he isn’t keen on making a formal offer for the company, preferring instead to let bosses get on with what they’re doing.

They will no doubt seek out his advice should they need to, though, especially given his track record and reputation within the biotech sector.

His turnaround of Pharmacylicals, the company which developed blockbuster cancer drug Imbruvica, culminated in its sale to US pharma giant AbbVie Inc (NYSE:ABBT) for US$21bn back in 2015, making him a billionaire in the process.

Before that, Duggan had already had success building and selling companies, although his investments – Computer Motion and Computer Machinery Corp, for example – tended to have more of a focus.

Son’s death sparked pharma interest

It was only after the death of his son from brain cancer back in 2004 that his interest in developing new, potentially life-changing drugs really piqued.

The keen surfer began buying up shares in Pharmacyclics for under US$10, with the stock having suffered various regulatory setbacks and close to collapse.

When he took the helm in 2008, he prioritised the development of Imbruvica, the success of which propped up the stock price and prompted AbbVie to cough up US$261.25 a share seven years later.

Duggan, a keen surfer who now lives in Florida, has used the huge payday from Pharmacyclicals to invest in other pharma firms.

He is the chairman and largest shareholder of Pulse Biosciences Inc (NASDAQ:PLSE) – a US$200mln company which is trying to harness the power of electricity to shock the immune system into producing a positive response.

Mates with Tom Cruise (possibly)

His money has also gone into one of his other passions: the Church of Scientology.

Duggan is often cited as the wealthiest member of the Church of Scientology and is rumoured to be the church’s biggest financial backer.

According to reports, he has donated tens of millions in the name of religion over the past decade or so, claiming in one interview that it is an “honour and personal obligation” to share his financial success with Scientology.

Quick facts: Summit Therapeutics PLC

Price: - -

Market: AIM
Market Cap: -


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...



Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

on 9/12/19

3 min read